论文部分内容阅读
目的:探究左乙拉西坦对癫痫患儿的临床疗效以及对其免疫功能的影响。方法:选择2014年10月-2015年11月我院收治的癫痫患儿133例为研究对象,随机给予66例患者左乙拉西坦治疗,给予67例患者托吡酯治疗,两组均持续治疗3个月。检测两组治疗前后淋巴细胞亚群水平(CD3~+、CD4~+、CD8~+、CD4~+/CD8~+)、血清免疫球蛋白水平(IgA、IgM、IgG),观察分析两组临床疗效及在治疗过程中出现的不良反应。结果:左乙拉西坦组总有效率为93.94%,托吡酯组为89.55%,差异无统计学意义(P>0.05)。治疗后左两组血清IgA、IgG、CD8~+水平均较治疗前降低(P<0.05),且左乙拉西坦组显著低于托吡酯组(P<0.05),而两组CD3~+、CD4~+、D4~+/CD8~+水平均明显上升(P<0.05),且左乙拉西坦组显著高于托吡酯组(P<0.05)。左乙拉西坦组总不良反应发生率为10.61%,显著低于托吡酯组的17.91%(P<0.05)。结论:左乙拉西坦能够有效控制癫痫患儿的临床症状,用药安全可靠,同时能够有效改善患儿的免疫功能,值得在临床上推广使用。
Objective: To investigate the clinical efficacy of levetiracetam in children with epilepsy and its impact on immune function. Methods: A total of 133 children with epilepsy treated in our hospital from October 2014 to November 2015 were enrolled. Sixty-six patients were treated with levetiracetam, and 67 patients were given topiramate. The patients in both groups were treated 3 Months. The level of lymphocyte subsets (CD3 +, CD4 +, CD8 +, CD4 + / CD8 +) and serum immunoglobulin levels (IgA, IgM, IgG) were measured before and after treatment. Efficacy and adverse reactions in the course of treatment. Results: The total effective rate was 93.94% in levetiracetam group and 89.55% in topiramate group, the difference was not statistically significant (P> 0.05). Serum levels of IgA, IgG and CD8 ~ + in the left two groups after treatment were lower than those before treatment (P <0.05), and those in the levetiracetam group were significantly lower than those in the topiramate group (P <0.05) CD4 ~ +, D4 ~ + / CD8 ~ + levels were significantly increased (P <0.05), and levetiracetam group was significantly higher than the topiramate group (P <0.05). The incidence of adverse reactions in levetiracetam group was 10.61%, which was significantly lower than that in topiramate group (17.91%, P <0.05). Conclusion: Levetiracetam can effectively control the clinical symptoms of children with epilepsy, safe and reliable medication, and can effectively improve children’s immune function, it is worth promoting in clinical use.